NRx Pharmaceuticals
Mr. Chaim Hurvitz has been the Chief Executive Officer of CH Health since May 2011. He previously served as the President of Teva International Group at Teva Pharmaceutical Industries Ltd from April 2002 to 2010 was a Director and member of the senior management of Teva Pharmaceuticals Industries Ltd. He serves as the Chairman of Galmed Pharmaceuticals Ltd. and has been its Director since 2011. He has been a Director of TheraCoat Ltd. since October 2010. He is a member of the management of the Manufacturers Association of Israel and head of its pharmaceutical branch. Mr. Hurvitz holds a Bachelor of Arts degree in political science and economics from Tel Aviv University, which was awarded in 1985.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
NRx Pharmaceuticals
NRx is a clinical-stage pharmaceutical company that is developing ZYESAMI (aviptadil acetate) for COVID-19 and NRX-101, the first oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder.